Table 2.
Some tyrosine kinase inhibitors used in clinical practice. Reproduced with permission from [103]. Copyright 2010 Elsevier.
| Tyrosine Kinase Inhibitor | Kinase Target(s) | FDA-Approved Indications |
|---|---|---|
| Dasatinib (Sprycel) | SRC, SFKs, BCR-ABL, c-KIT, PDGFR, c-FMS, EPHA2 | CML (2nd-line), Ph + ALL |
| Erlotinib (Tarceva) | EGFR | NSCLC |
| Gefitinib (Iressa) | EGFR | NSCLC |
| Imatinib (Gleevec/Glivec) | BCR-ABL, c-KIT, PDGFR | CML, Ph + ALL, GIST |
| Lapatinib (Tykerb) | EGFR, HER2/neu | Advanced breast cancer |
| Nilotinib (Tasigna) | BCR-ABL, c-KIT, PDGFR | CML (2nd-line) |
| Sorafenib (Nexavar) | VEGFR, PDGFR | Renal cell carcinoma, hepatocellular carcinoma |
| Sunitinib (Sutent) | VEGFR2, PDGFR, c-KIT, FLT3 | GIST, renal cell carcinoma |
CML, chronic myeloid leukemia; EGFR, epidermal growth factor receptor; EPHA, ephrin A; FLT3, FMS-like tyrosine kinase 3; GIST, gastrointestinal stromal tumours; NSCLC, non-small cell lung carcinoma; PDGFR, platelet-derived growth factor receptor; Ph + ALL, Philadelphia chromosome–positive acute lymphoblastic leukemia; VEGFR2, vascular endothelial growth factor receptor-2.